Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety

Abstract

The article discusses the place of CD38 antibodies in the treatment of multiple myeloma (MM). Special emphasis is put of isatuximab. In 2020, isatuximab in combination with pomalidomide and dexamethasone was approved in Russia for the treatment of adult patients with MM who have received at least two lines therapies, including lenalidomide and a proteasome inhibitor. The published data from studies of isatuximab, demonstrating its clinical efficacy and safety in combination with standard treatment regimens for recurrent/refractory MM, are discussed.

Keywords

• cd38
• antibody
• isatuximab
• multiple myeloma